Home Healthcare Healthcare Services Healthcare Contract Manufacturing Market

Healthcare Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Medical Devices, Pharmaceuticals) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 05, 2026 | Author: Debashree Bora | Format:

Healthcare Contract Manufacturing Market Size Analysis 

The global healthcare contract manufacturing market size was valued at USD 427.74 billion in 2025 and is projected to grow from USD 508.16 billion in 2026 to USD 2016.17 billion by 2034, registering a CAGR of 18.8% . Asia Pacific dominated the healthcare contract manufacturing market with a share of 38.4% in 2025.

Healthcare contract manufacturing is the process of outsourcing the production of medical and healthcare products to specialized third-party manufacturers. It includes the manufacturing, assembly, packaging, and testing of pharmaceuticals, medical devices, diagnostic equipment, and healthcare supplies while helping companies improve production efficiency and manage costs.

Healthcare Contract Manufacturing Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 427.74 Billion
2026 Market Size
USD 508.16 Billion
2034 Projected Market Size
USD 2016.17 Billion
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
18.8%

Regional Insights

Largest Regional Market (2025)
Asia Pacific
Asia Pacific Market Share (2025)
38.4%
Fastest-growing Region
North America
North America CAGR (2026–2034)
10.9%

Segment Insights

By Type
Fastest-growing Segment
Pharmaceuticals
CAGR(2026–2034) 10.1%
By Services
Leading Segment
Component Manufacturing
Market Share in 2025 31.4%
By Indication
Fastest-growing Segment
Drug Delivery
CAGR (2026–2034) 11.1%
By Service
Leading Segment
API/bulk drugs
Market Share in 2025 34.8%
Healthcare Contract Manufacturing Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

Healthcare Contract Manufacturing Market Dynamics

01

Pharmaceutical Outsourcing Strategies Drive Market

Pharmaceutical companies outsource drug production to reduce manufacturing costs, improve operational flexibility, and focus on research and commercialization. For example, companies may partner with contract manufacturers for tablet, capsule, and injectable production, supporting demand for external manufacturing capacity and specialized services.

02

Biopharmaceutical Product Development Market Demand

The development of biologics, vaccines, and complex therapies requires specialized facilities, technical expertise, and strict quality controls. For example, biotechnology companies may outsource the production of monoclonal antibodies to qualified manufacturing partners, creating opportunities for contract manufacturers with biologics production capabilities.

03

Impact Analysis of Key Drivers in Healthcare Contract Manufacturing Market

DriversMarket Impact

Pharmaceutical Outsourcing Strategies

Pharmaceutical companies outsource production activities to reduce infrastructure costs and focus on research and commercialization, supporting contracts with third-party manufacturers.

Biopharmaceutical Product Development

The development of biologics and complex therapies requires specialized manufacturing capabilities, creating opportunities for contract manufacturers with advanced production facilities.

Expansion of Generic Drug Manufacturing

Pharmaceutical companies use external manufacturing partners to manage production volumes and control costs, supporting contract manufacturing of generic medicines.

Medical Device Production Outsourcing

Medical device companies outsource component manufacturing and assembly to access specialized equipment and technical expertise, supporting third-party production services.

Stringent Quality and Regulatory Requirements

Compliance with Good Manufacturing Practices and regulatory standards encourages pharmaceutical companies to work with qualified contract manufacturers that maintain validated facilities and quality systems.

Pharmaceutical Supply Chain Optimization

Companies diversify manufacturing partners to improve production flexibility and reduce supply interruptions, supporting long-term outsourcing agreements.

01

Stringent Regulatory Compliance Requirements Restrain Market Expansion

Strict regulatory standards require contract manufacturers to maintain detailed documentation, validated processes, and regular quality audits. Compliance requirements across different markets can lengthen approval timelines and delay the execution of outsourced manufacturing projects.

02

Quality Control and Batch Consistency Challenges

Variations in raw materials, production conditions, and process controls can affect the quality and uniformity of manufacturing batches. Batch failures may lead to product rejection and supply delays, reducing client confidence and limiting outsourcing partnerships.

03

Impact Analysis of Key Restraints in Healthcare Contract Manufacturing Market

RestraintsMarket Impact

Stringent Regulatory Compliance Requirements

Contract manufacturers must follow strict pharmaceutical regulations, quality standards, and documentation requirements across different markets. Frequent audits and compliance updates can delay production approvals and restrict the onboarding of new manufacturing projects.

Quality Control and Batch Consistency Challenges

Variations in raw materials, production processes, and equipment performance can affect product quality across manufacturing batches. These inconsistencies may lead to rejected batches, production delays, and reduced client confidence.

Intellectual Property and Confidentiality Risks

Sharing proprietary formulations, process data, and product information with external manufacturers can create concerns about intellectual property protection. These risks may discourage pharmaceutical companies from outsourcing sensitive manufacturing activities.

Supply Chain Disruptions for Critical Materials

Shortages of active pharmaceutical ingredients, specialized excipients, and sterile packaging materials can interrupt manufacturing schedules. Delayed material availability may affect order fulfillment and limit production reliability.

Limited Capacity for Specialized Manufacturing

The availability of facilities for sterile production, biologics, and advanced drug formulations remains limited in some regions. Capacity constraints can restrict outsourcing options and delay the commercialization of complex pharmaceutical products.

01

Lyophilization Services Offers Growth Opportunities

Biopharmaceutical manufacturers, vaccine developers, and pharmaceutical companies benefit from lyophilization services that improve product stability and extend shelf life. Specialized freeze-drying facilities, formulation development, and contract manufacturing create revenue avenues for providers such as Catalent, Thermo Fisher Scientific, and Recipharm.

02

Pharmaceutical Serialization Services

Pharmaceutical manufacturers and packaging companies benefit from serialization services that improve product traceability and support regulatory compliance. Serialization software, packaging-line integration, and ongoing data management create revenue opportunities for companies such as Antares Vision, TraceLink, and OPTEL, supporting healthcare contract manufacturing market growth.

Healthcare Contract Manufacturing Market Segmentation Analysis

By Type

The medical devices segment is likely to witness a growth rate of 9.4% CAGR during the forecast period. This growth is driven by increasing demand for specialized medical equipment, advancements in device technologies, and the growing need for reliable manufacturing services.

The pharmaceuticals segment is likely to witness a growth rate of 10.1% CAGR during the forecast period. This growth is driven by rising drug development activities, increasing pharmaceutical outsourcing, and the need for specialized production capabilities.

Healthcare Contract Manufacturing Market Size By Segments

Request Customizationto receive a tailored report.

By Services

The component manufacturing segment dominated the services segment with a share of 31.4% in 2025 due to the growing need for precision-engineered components and reliable medical product manufacturing.

The devices manufacturing segment is likely to witness a growth rate of 9.1% CAGR during the forecast period. This growth is driven by increasing demand for outsourced medical device production, the need for specialized manufacturing capabilities, and rising adoption of advanced medical technologies.

By Indication

The cardiology segment dominated the indication segment with a share of 17.6% in 2025 due to the high prevalence of cardiovascular diseases and the continued need for medical devices and pharmaceutical products used in cardiac care.

The drug delivery segment is likely to witness the fastest growth at a CAGR of 11.1% during the forecast period. This growth is driven by advancements in drug delivery technologies, demand for targeted therapies, and the development of patient-friendly administration systems.

By Service

The API/bulk drugs segment dominated the service segment with a share of 34.8% in 2025 due to its essential role in pharmaceutical production and the growing reliance on external suppliers for active pharmaceutical ingredients.

The advanced drug delivery formulations segment is likely to witness the fastest growth at a CAGR of 11.4% during the forecast period. This growth is driven by the need for improved drug absorption, controlled release, and targeted delivery solutions that support better treatment outcomes.

Healthcare Contract Manufacturing Market Share By Segments

Speak to an Analystto discuss market opportunities.

Healthcare Contract Manufacturing Market Regional Outlook

Asia Pacific Healthcare Contract Manufacturing Market 

The Asia Pacific healthcare contract manufacturing market accounted for the dominant share of 38.4% in 2025.

Japan Healthcare Contract Manufacturing Market 

In October 2026, Fujifilm announced plans to install linker-payload manufacturing equipment at its Hirono plant, creating Japan’s first one-stop CDMO service for antibody-drug conjugate components. In July, AGC Biologics secured a long-term manufacturing agreement with a global biopharmaceutical company, with the Yokohama site progressing toward commercial production in 2027.

China Healthcare Contract Manufacturing Market 

The National Medical Products Administration issued updated contract-manufacturing requirements in April 2026, reinforcing GMP compliance, technical-transfer checks, and quality responsibilities for contract manufacturers. Shanghai also introduced measures to support contract research and manufacturing organisations, local production, and the transfer of overseas medicines and medical devices into domestic manufacturing.

India Healthcare Contract Manufacturing Market 

The government reported in March 2026 that the pharmaceutical PLI scheme had attracted cumulative investment of INR 41,943 crore and generated sales of INR 3,35,036 crore across 1,988 products by December 2025. Separately, the bulk-drug PLI scheme had supported 48 approved greenfield projects, helping strengthen domestic supplies of APIs and intermediates used by pharmaceutical manufacturers and outsourcing partners.

Asia Pacific Healthcare Contract Manufacturing Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

North America Healthcare Contract Manufacturing Market 

The North America healthcare contract manufacturing market is expected to grow at a CAGR of 10.9% during the forecast period.

U.S. Healthcare Contract Manufacturing Market 

On november 3, 2026, lonza agreed to acquire five U.S. CDMO manufacturing sites from Merck, adding capabilities in bioconjugates, payload-linkers, viral vectors, and advanced drug delivery. Separately, Cambrex broke ground on a USD 120 million expansion in Iowa on October 30, which will add 160,000 litres of manufacturing capacity for small-molecule APIs and synthetic peptides.

Canada Healthcare Contract Manufacturing Market 

In february 2026, bora pharmaceuticals renewed a five-year, USD 250 million manufacturing agreement with GSK covering more than 20 commercial product lines and over 335 products, with production involving its Mississauga facility. In August, the Canadian government announced support for Evonik’s Vancouver GMP facility, which will manufacture specialised lipids for mRNA medicines and gene therapies, strengthening advanced drug manufacturing services.

Europe Healthcare Contract Manufacturing Market 

The Europe healthcare contract manufacturing market accounted for 21.3% of the global market in 2025.

U.K. Healthcare Contract Manufacturing Market 

In february 2026, FUJIFILM biotechnologies opened an expanded biologics manufacturing facility in Teesside following an investment of approximately £400 million. The site includes single-use bioreactors with a total capacity of up to 19,000 litres, adding contract manufacturing capacity for antibodies and other biologic medicines.

Germany Healthcare Contract Manufacturing Market 

In may 2026, vetter began construction of a new commercial injectable-drug manufacturing site in Saarlouis, with planned investment approaching €500 million and commissioning targeted for 2031. In September, ROTOP broke ground on a new contract manufacturing centre for radiopharmaceuticals, initially designed to produce around 70,000 sterile patient doses annually.

Competitive Landscape

The healthcare contract manufacturing market  is moderately fragmented, with contract development and manufacturing organizations (CDMOs), pharmaceutical manufacturers, medical device manufacturers, and specialized outsourcing providers competing in this space.Key players such as Jabil, Inc., Celestica, Inc., Integer Holdings, Plexus, and Sanmina  are estimated to collectively account for 20–25% of the global healthcare contract manufacturing market share.

Established players compete through production capacity, regulatory compliance, quality standards, technological capabilities, and global manufacturing networks, while the healthcare contract manufacturing market ecosystem also includes emerging players that focus on cost-effective services, flexible production models, specialized manufacturing solutions, and advanced process technologies.

List of Key and Emerging Players in Healthcare Contract Manufacturing Market

Jabil, Inc. (U.S.)
Celestica Inc. (Canada)
Integer Holdings Corporation (U.S.)
Plexus Corp. (U.S.)
Sanmina Corporation (U.S.)
West Pharmaceutical Services, Inc. (U.S.)
Flex Ltd. (Singapore)
Viant Medical, Inc. (U.S.)
Synecco Ltd. (Ireland)
Nordson Corporation (U.S.)
Catalent, Inc. (U.S.)

Key Industry Developments

September 2026
Neuland Laboratories commenced operations at the first module of its commercial peptide manufacturing facility in India. The module adds 7,000 litres of reactor capacity for peptide API development and commercial production, strengthening outsourced manufacturing capabilities for complex peptide drugs.
June 2026
PCI Pharma Services acquired Ajinomoto Althea, expanding its sterile fill-finish manufacturing, aseptic drug product development, and advanced injectable manufacturing capabilities for biopharmaceutical customers.
May 2026
Catalent expanded commercial-scale biologics manufacturing capacity by investing in advanced production technologies and digital manufacturing capabilities to support growing demand for outsourced pharmaceutical manufacturing services.
February 2026
Recipharm expanded its injectable manufacturing operations by adding new aseptic filling lines and analytical laboratories to strengthen contract development and manufacturing services for global pharmaceutical companies.

Report Scope

Segmentation

By Type 2
  • Medical Devices
  • Pharmaceuticals

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Jabil, Inc. (U.S.) · Celestica Inc. (Canada) · Integer Holdings Corporation (U.S.) · Plexus Corp. (U.S.) · Sanmina Corporation (U.S.)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The healthcare contract manufacturing market size is valued at USD 508.16 Billion in 2026 and is projected to reach USD 2016.17 Billion by 2034, at a CAGR of 18.8% during the forecast period 2026-2034.
Asia Pacific dominated the market with a share of 38.4% in 2025.
The leading players in this market are Jabil, Inc., Celestica, Inc., Integer Holdings Corp..
The healthcare contract manufacturing market is projected to grow at a CAGR of 18.8% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now